Name: MERSANA THERAPEUTICS INC (MRSN) Stock
Brand: MERSANA THERAPEUTICS INC
Rating: 5.5 (3 reviews)

MRSN Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Halper Sadeh LLC - Mentions: CDTX RYI

Halper Sadeh LLC Encourages MRSN, CDTX, RYI Shareholders to Contact the Firm to Discuss Their Rights

13 days ago - By: Halper Sadeh LLC - Mentions: SEE EXAS

Halper Sadeh LLC Encourages SEE, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their Rights

a month ago - By: Benzinga

Mersana Therapeutics Earnings Preview

a month ago - By: Investor's Business Daily - Mentions: DAWN

Mersana Catapults 200% On Day One Bio's Surprise Buyout

4 months ago - By: The Motley Fool

Mersana Misses Fiscal Q2 Revenue Target

24 days ago - By: Kahn Swick & Foti, LLC

Mersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc. - MRSN

26 days ago - By: Brodsky & Smith LLC - Mentions: CDTX THS GIFI

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Cidara Therapeutics, Inc. (Nasdaq - CDTX), Mersana Therapeutics, Inc. (Nasdaq - MRSN), TreeHouse Foods Inc. (NYSE - THS), Gulf Island Inc. (Nasdaq - GIFI)

4 months ago - By: Benzinga

A Look at Mersana Therapeutics's Upcoming Earnings Report

a month ago - By: Zacks Investment Research - Mentions: CLSD

Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue Estimates

a month ago - By: Halper Sadeh LLC - Mentions: THS HBAN

Halper Sadeh LLC Encourages MRSN, THS, HBAN Shareholders to Contact the Firm to Discuss Their Rights

a month ago - By: Mersana Therapeutics, Inc.

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2025 Financial Results

a month ago - By: Stocktwits - Mentions: DAWN

Mersana Therapeutics Stock Explodes Over 200% To Notch Best Day Ever As $285M Buyout Trumps Analyst Downgrades: Retail Cheers ‘Very Good Bargain’

a month ago - By: Ademi LLP

Shareholder Alert: The Ademi Firm investigates whether Mersana Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

a month ago - By: Zacks Investment Research - Mentions: CLNN

Clene Inc. (CLNN) Reports Q3 Loss, Lags Revenue Estimates

a month ago - By: Halper Sadeh LLC

MRSN Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Mersana Therapeutics, Inc. is Fair to Shareholders

a month ago - By: Stocktwits - Mentions: DAWN

MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal

a month ago - By: Mersana Therapeutics, Inc.

Day One Biopharmaceuticals to Acquire Mersana Therapeutics

a month ago - By: Zacks Investment Research - Mentions: CUE

Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Lags Revenue Estimates

a month ago - By: Mersana Therapeutics, Inc.

Mersana Therapeutics to Host Third Quarter 2025 Conference Call on November 14, 2025

a month ago - By: Zacks Investment Research - Mentions: CRIS

Curis (CRIS) Reports Q3 Loss, Beats Revenue Estimates

a month ago - By: Zacks Investment Research - Mentions: RPRX

Royalty Pharma (RPRX) Beats Q3 Earnings and Revenue Estimates

3 months ago - By: Zacks Investment Research

Wall Street Analysts See a 314.81% Upside in Mersana Therapeutics (MRSN): Can the Stock Really Move This High?

4 months ago - By: Zacks Investment Research

Wall Street Analysts Think Mersana Therapeutics (MRSN) Could Surge 248.83%: Read This Before Placing a Bet

4 months ago - By: Zacks Investment Research - Mentions: RNA

Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue Estimates

4 months ago - By: Mersana Therapeutics, Inc.

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results

4 months ago - By: Zacks Investment Research - Mentions: STOK

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

4 months ago - By: Zacks Investment Research - Mentions: VTGN

VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates

4 months ago - By: Mersana Therapeutics, Inc.

MERSANA THERAPEUTICS INC (MRSN) Stock News

MRSN Latest News, Press Relases and Analysis

Halper Sadeh LLC Encourages MRSN, CDTX, RYI Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages SEE, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their Rights

Mersana Therapeutics Earnings Preview

Mersana Catapults 200% On Day One Bio's Surprise Buyout

Mersana Misses Fiscal Q2 Revenue Target

Mersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc. - MRSN

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Cidara Therapeutics, Inc. (Nasdaq - CDTX), Mersana Therapeutics, Inc. (Nasdaq - MRSN), TreeHouse Foods Inc. (NYSE - THS), Gulf Island Inc. (Nasdaq - GIFI)

A Look at Mersana Therapeutics's Upcoming Earnings Report

Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue Estimates

Halper Sadeh LLC Encourages MRSN, THS, HBAN Shareholders to Contact the Firm to Discuss Their Rights

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2025 Financial Results

Mersana Therapeutics Stock Explodes Over 200% To Notch Best Day Ever As $285M Buyout Trumps Analyst Downgrades: Retail Cheers ‘Very Good Bargain’

Shareholder Alert: The Ademi Firm investigates whether Mersana Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

Clene Inc. (CLNN) Reports Q3 Loss, Lags Revenue Estimates

MRSN Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Mersana Therapeutics, Inc. is Fair to Shareholders

MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal

Day One Biopharmaceuticals to Acquire Mersana Therapeutics

Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Lags Revenue Estimates

Mersana Therapeutics to Host Third Quarter 2025 Conference Call on November 14, 2025

Curis (CRIS) Reports Q3 Loss, Beats Revenue Estimates

Royalty Pharma (RPRX) Beats Q3 Earnings and Revenue Estimates

Wall Street Analysts See a 314.81% Upside in Mersana Therapeutics (MRSN): Can the Stock Really Move This High?

Wall Street Analysts Think Mersana Therapeutics (MRSN) Could Surge 248.83%: Read This Before Placing a Bet

Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue Estimates

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates

Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025